Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

INTRODUCTION: Previous clinical trials established the efficacy and safety of sucrose-formulated recombinant factor (F) VIII (rFVIII-FS/Kogenate FS®/Helixate FS®) and octocog alfa (BAY 81–8973/Kovaltry®; LEOPOLD trials). AIM: To report the results of a post hoc subgroup analysis assessing efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenet, Gili, Moulton, Thomas, Wicklund, Brian M, Ahuja, Sanjay P, Escobar, Miguel, Mahlangu, Johnny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257928/
https://www.ncbi.nlm.nih.gov/pubmed/37309365
http://dx.doi.org/10.2147/JBM.S405624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257928/
https://www.ncbi.nlm.nih.gov/pubmed/37309365
http://dx.doi.org/10.2147/JBM.S405624

Ejemplares similares